Neutralizing antibody responses to SARS-CoV-2, though often of limited longevity, have generally been assumed to be protective against COVID-19 disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880617 | PMC |
| http://dx.doi.org/10.1126/sciimmunol.abf8870 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 Pneumonia Diagnosed by Bronchoalveolar Lavage Fluid, With CD4 T-cell Depletion Contributing to Prolonged Infection: Two Case Reports.
Cureus
November 2024
Internal Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, JPN.
Article Synopsis
- Patients treated with CD20 antibodies face a higher risk of severe COVID-19 infections, even if they test negative in nasal swabs.
- Bronchoalveolar lavage is crucial for accurate diagnosis of COVID-19 pneumonia in these patients, especially when CT scans show signs of viral pneumonia.
- CD4 T-cell depletion and low humoral immune responses due to treatments like bendamustine may contribute to ongoing COVID-19 issues, despite the presence of neutralizing antibodies.
Pathophysiology of rejection in kidney transplantation.
Expert Rev Clin Immunol
December 2024
Independent Researcher, Milan, Italy.
Introduction: Rejection remains a major obstacle to successful kidney transplantation. The complex pathophysiology of rejection depends on a fine-tuned interplay between the innate and adaptive immune systems.
Areas Covered: This review provides a comprehensive analysis of the pathophysiology of rejection of kidney grafts, performed through careful selection of most relevant papers available on the topic in the PubMed database.
Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection.
Cureus
September 2024
Medical Microbiology and Immunology, Plovdiv Medical University, Plovdiv, BGR.
This case report aims to elucidate the unique clinical course of a 34-year-old male patient diagnosed with human immunodeficiency virus (HIV), chronic hepatitis C, and prior tuberculosis (TB) infections, who subsequently contracted COVID-19. Immunological assessments revealed profound immunosuppression, marked by decreased CD4+ T cells (0.037 x 10⁹/L), alongside mildly elevated IgG levels (16.
View Article and Find Full Text PDFTherapeutic glycan-specific antibody binding mediates protection during primary amoebic meningoencephalitis.
Infect Immun
October 2024
Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
() infection the upper respiratory tract causes a fatal CNS disease known as primary amoebic meningoencephalitis (PAM). The robust immune response to underlies the immunopathology that characterizes the disease. However, little is known about why this pathogen evades immune control.
View Article and Find Full Text PDFThe use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.
Front Med (Lausanne)
June 2024
Transplant Center, University Hospital Munich, Ludwig-Maximilians-University (LMU), Munich, Germany.
The calcineurin inhibitor tacrolimus, which is available as an immediate- or extended-release formulation, is the standard-of-care immunosuppression after kidney transplantation with low rejection rates, especially in the first year after transplantation. However, its highly variable metabolism rate, narrow therapeutic window, and nephrotoxic side effects require close drug monitoring and individual dosing. Here, we describe first the application of extended-release tacrolimus (ER-Tac) twice daily with beneficial effects in a kidney transplant recipient under extensive therapeutic drug monitoring.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!